Does the media prefer INBX or CCCC?

In the previous week, Inhibrx Biosciences had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 6 mentions for Inhibrx Biosciences and 3 mentions for C4 Therapeutics. Inhibrx Biosciences' average media sentiment score of 1.49 beat C4 Therapeutics' score of 1.11 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXRX or CCCC?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Recursion Pharmaceuticals and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.11 beat Recursion Pharmaceuticals' score of 0.66 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SEPN or CCCC?

Septerna has higher revenue and earnings than C4 Therapeutics. Septerna is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 37.38 -$48.88M -$0.54 N/A C4 Therapeutics $35.95M 12.80 -$104.99M -$1.00 N/A

Is SEPN or CCCC more profitable?

Septerna has a net margin of -24.51% compared to C4 Therapeutics' net margin of -289.44%. Septerna's return on equity of -9.57% beat C4 Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Septerna -24.51% -9.57% -6.28% C4 Therapeutics -289.44% -45.45% -30.90%

Does the media prefer SEPN or CCCC?

In the previous week, Septerna had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Septerna and 3 mentions for C4 Therapeutics. Septerna's average media sentiment score of 1.31 beat C4 Therapeutics' score of 1.11 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NTLA or CCCC?

In the previous week, Intellia Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for Intellia Therapeutics and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.11 beat Intellia Therapeutics' score of 1.10 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

C4 Therapeutics (CCCC) Competitors

$3.74 -0.05 (-1.32%)

As of 09/3/2026 04:00 PM Eastern

Compare

CCCC vs. TSHA, INBX, RXRX, SEPN, and NTLA

Should you buy C4 Therapeutics stock or one of its competitors? C4 Therapeutics's main competitors and comparable companies include Taysha Gene Therapies (TSHA), Inhibrx Biosciences (INBX), Recursion Pharmaceuticals (RXRX), Septerna (SEPN), and Intellia Therapeutics (NTLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does C4 Therapeutics compare to Taysha Gene Therapies?

C4 Therapeutics (NASDAQ:CCCC) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, C4 Therapeutics had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 3 mentions for C4 Therapeutics and 0 mentions for Taysha Gene Therapies. C4 Therapeutics' average media sentiment score of 1.11 beat Taysha Gene Therapies' score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
C4 Therapeutics	Positive
Taysha Gene Therapies	Neutral

C4 Therapeutics has a beta of 2.94, meaning that its share price is 194% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

C4 Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 104.99%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 129.25%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Taysha Gene Therapies has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -45.45% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

C4 Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	12.80	-$104.99M	-$1.00	N/A
Taysha Gene Therapies	$9.77M	185.76	-$109M	-$0.42	N/A

Summary

C4 Therapeutics beats Taysha Gene Therapies on 10 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Inhibrx Biosciences currently has a consensus target price of $197.50, suggesting a potential upside of 61.54%. C4 Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 104.99%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Inhibrx Biosciences had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 6 mentions for Inhibrx Biosciences and 3 mentions for C4 Therapeutics. Inhibrx Biosciences' average media sentiment score of 1.49 beat C4 Therapeutics' score of 1.11 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

C4 Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,384.36	-$140.05M	-$8.88	N/A
C4 Therapeutics	$35.95M	12.80	-$104.99M	-$1.00	N/A

Inhibrx Biosciences has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -45.45% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Inhibrx Biosciences has a beta of 3.66, indicating that its share price is 266% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.94, indicating that its share price is 194% more volatile than the broader market.

Summary

C4 Therapeutics beats Inhibrx Biosciences on 9 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

C4 Therapeutics has a net margin of -289.44% compared to Recursion Pharmaceuticals' net margin of -945.94%. C4 Therapeutics' return on equity of -45.45% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

Recursion Pharmaceuticals currently has a consensus target price of $8.06, suggesting a potential upside of 134.30%. C4 Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 104.99%. Given Recursion Pharmaceuticals' higher probable upside, research analysts clearly believe Recursion Pharmaceuticals is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Recursion Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.94, meaning that its stock price is 194% more volatile than the broader market.

C4 Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. C4 Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	24.66	-$644.76M	-$1.04	N/A
C4 Therapeutics	$35.95M	12.80	-$104.99M	-$1.00	N/A

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Recursion Pharmaceuticals and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.11 beat Recursion Pharmaceuticals' score of 0.66 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

C4 Therapeutics beats Recursion Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Septerna has higher revenue and earnings than C4 Therapeutics. Septerna is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	37.38	-$48.88M	-$0.54	N/A
C4 Therapeutics	$35.95M	12.80	-$104.99M	-$1.00	N/A

In the previous week, Septerna had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Septerna and 3 mentions for C4 Therapeutics. Septerna's average media sentiment score of 1.31 beat C4 Therapeutics' score of 1.11 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of C4 Therapeutics shares are held by institutional investors. 5.8% of Septerna shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Septerna has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.94, indicating that its stock price is 194% more volatile than the broader market.

Septerna presently has a consensus target price of $52.44, indicating a potential upside of 42.51%. C4 Therapeutics has a consensus target price of $7.67, indicating a potential upside of 104.99%. Given C4 Therapeutics' higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Septerna has a net margin of -24.51% compared to C4 Therapeutics' net margin of -289.44%. Septerna's return on equity of -9.57% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

Summary

Septerna beats C4 Therapeutics on 13 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

C4 Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	26.26	-$412.69M	-$3.36	N/A
C4 Therapeutics	$35.95M	12.80	-$104.99M	-$1.00	N/A

In the previous week, Intellia Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for Intellia Therapeutics and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.11 beat Intellia Therapeutics' score of 1.10 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.94, suggesting that its stock price is 194% more volatile than the broader market.

Intellia Therapeutics currently has a consensus price target of $21.15, suggesting a potential upside of 66.82%. C4 Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 104.99%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

C4 Therapeutics has a net margin of -289.44% compared to Intellia Therapeutics' net margin of -672.16%. C4 Therapeutics' return on equity of -45.45% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

Summary

C4 Therapeutics beats Intellia Therapeutics on 11 of the 17 factors compared between the two stocks.

Get C4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CCCC vs. The Competition

Export

Metric	C4 Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$466.27M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-3.74	12.66	273.29	25.38
Price / Sales	12.80	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.86	16.29	12.89	6.14
Net Income	-$104.99M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.86%	0.34%	0.60%	-0.27%
1 Month Performance	3.60%	8.52%	5.73%	0.68%
1 Year Performance	40.07%	52.66%	25.35%	14.84%

C4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CCCC C4 Therapeutics	1.5253 of 5 stars	$3.74 -1.3%	$7.67 +105.0%	+46.1%	$466.27M	$35.95M	N/A	150	News Coverage Positive News
TSHA Taysha Gene Therapies	2.1717 of 5 stars	$5.67 -0.4%	$12.77 +125.4%	+92.1%	$1.85B	$9.77M	N/A	180
INBX Inhibrx Biosciences	3.0432 of 5 stars	$122.09 -3.6%	$197.50 +61.8%	+339.8%	$1.80B	$1.30M	N/A	166	Positive News
RXRX Recursion Pharmaceuticals	1.6834 of 5 stars	$3.34 -1.9%	$8.06 +141.7%	-25.7%	$1.79B	$74.68M	N/A	400	Insider Trade
SEPN Septerna	3.3683 of 5 stars	$38.19 +0.1%	$52.44 +37.3%	+161.4%	$1.78B	$45.95M	N/A	N/A	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CCCC) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

C4 Therapeutics (CCCC) Competitors

CCCC vs. TSHA, INBX, RXRX, SEPN, and NTLA

How does C4 Therapeutics compare to Taysha Gene Therapies?

Summary

How does C4 Therapeutics compare to Inhibrx Biosciences?

Summary

How does C4 Therapeutics compare to Recursion Pharmaceuticals?

Summary

How does C4 Therapeutics compare to Septerna?

Summary

How does C4 Therapeutics compare to Intellia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

C4 Therapeutics (CCCC) Competitors

CCCC vs. TSHA, INBX, RXRX, SEPN, and NTLA

How does C4 Therapeutics compare to Taysha Gene Therapies?

Do institutionals & insiders hold more shares of CCCC or TSHA?

Does the media favor CCCC or TSHA?

Which has more risk & volatility, CCCC or TSHA?

Do analysts recommend CCCC or TSHA?

Is CCCC or TSHA more profitable?

Which has preferable earnings and valuation, CCCC or TSHA?

Summary

How does C4 Therapeutics compare to Inhibrx Biosciences?

Do analysts recommend INBX or CCCC?

Does the media prefer INBX or CCCC?

Which has preferable earnings & valuation, INBX or CCCC?

Is INBX or CCCC more profitable?

Do institutionals & insiders have more ownership in INBX or CCCC?

Which has more volatility and risk, INBX or CCCC?

Summary

How does C4 Therapeutics compare to Recursion Pharmaceuticals?

Do insiders & institutionals have more ownership in RXRX or CCCC?

Is RXRX or CCCC more profitable?

Do analysts recommend RXRX or CCCC?

Which has more volatility and risk, RXRX or CCCC?

Which has better earnings and valuation, RXRX or CCCC?

Does the media refer more to RXRX or CCCC?

Summary

How does C4 Therapeutics compare to Septerna?

Which has better earnings & valuation, SEPN or CCCC?

Does the media prefer SEPN or CCCC?

Do institutionals and insiders hold more shares of SEPN or CCCC?

Which has more risk & volatility, SEPN or CCCC?

Do analysts prefer SEPN or CCCC?

Is SEPN or CCCC more profitable?

Summary

How does C4 Therapeutics compare to Intellia Therapeutics?

Do institutionals & insiders have more ownership in NTLA or CCCC?

Which has stronger earnings & valuation, NTLA or CCCC?

Does the media prefer NTLA or CCCC?

Which has more volatility and risk, NTLA or CCCC?

Do analysts recommend NTLA or CCCC?

Is NTLA or CCCC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools